In this study, we analysed 133 ITAC for the presence of CD8+ TILs and TMIT, combining the presence of CD8+ TILs and the expression of PD-L1 on tumour cells as a possible predictive marker for treatment with PD-1/PD-L1 immune checkpoint inhibitors. This evidence concerns the gene CD8A and neoplasm.